Drug Channels

MARCH 4, 2025

Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCIs new live video webinar: PBM Industry Update: Trends, Challenges, and What's Ahead This event will be broadcast live on Friday, April 4, 2025, from 12:00 p.m. Drawing from the brand-new 2025 Economic Report on U.S.

Specialty Pharmacies 94

Specialty Pharmacies Drug Pricing Labelling 94

STAT

SEPTEMBER 23, 2022

billion in 2020 (three times higher than savings from 2019) and have the potential to increase to $133 billion by 2025. Generic & Biosimilar Medicines Savings Report” from the Association for Accessible Medicines, biosimilar savings in the U.S. Read the rest…

Biosimilars 235

Biosimilars Diabetes Drug Pricing 235

Drug Channels

DECEMBER 3, 2024

Minnesota just released the industry‘s first ever mandated financial report on the 340B Drug Pricing Program. During next week’s Drug Channels Outlook 2025 live video webinar, he'll tell you what's ahead for the program that continues to defy gravity. There are important limitations to these data.

Drug Pricing 52

Drug Pricing Hospitals 52

Drug Channels

APRIL 2, 2025

Minnesota just released the industrys first ever mandated financial report on the 340B Drug Pricing Program. Read more 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Click here to see the original post from December 2024. I suspect similar reports are gonna be popular.

Drug Pricing 52

Drug Pricing Hospitals 52

Pharmacy Times

JANUARY 21, 2025

At the start of 2025, 590 drug prices changed, with only 7 drugs seeing decreases in wholesale acquisition costs (WAC).

Drug Pricing 49

Drug Pricing 49

Drug Channels

MARCH 24, 2025

Informa Connects Life Sciences Pricing & Contracting USA May 19-21, 2025 | Philadelphia, PA Drug Channels readers save 10% with code 25DRCH10* Pricing & Contracting USA arrives at an important moment for our industry. 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.

Drug Pricing 52

Drug Pricing 52

Pharmaceutical Commerce

MARCH 28, 2025

The latest news for pharma industry insiders.

Drug Pricing 59

Drug Pricing 59

FDA Law Blog: Biosimilars

MARCH 12, 2025

The American Conference Institutes 21st Annual Paragraph IV Disputes is scheduled to take place from April 29-30, 2025 at The Altman Building in New York, NY. Widely recognized as the industry gold standard, the conference unites leaders from brand-name and generic drug companies, alongside federal judges, the U.S.

Drug Pricing 59

Drug Pricing 59

Putting Patients First Blog

APRIL 27, 2023

NHC Medicare Drug Price Negotiation Program Comments April 27, 2023 By: Allen Pinn, Coordinator, Policy April 14, the National Health Council (NHC) submitted comments to the Centers for Medicare & Medicaid Services (CMS) regarding the Medicare Drug Price Negotiation Program, established under the Inflation Reduction Act.

Drug Pricing 52

Drug Pricing 52

Pharmaceutical Technology

JANUARY 31, 2025

On 1 January 2025, important legal amendments relating to drug pricing in Germany included in the Medical Research Act came into legal force.

Drug Pricing 59

Drug Pricing 59

FDA Law Blog: Biosimilars

MARCH 18, 2025

Even though the PTE provisions established in the Drug Price Competition and Patent Restoration Act are forty-plus years old, courts are still grappling with questions about how to best implement the Patent Term Extension. On March 13, 2025, the Federal Circuit ventured into the world of reissued patents and PTE. (

Drug Pricing 59

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 59

Big Molecule Watch

NOVEMBER 6, 2023

The licensure and marketing of WEZLANA could affect negotiations with CMS regarding Medicare pricing for STELARA under the Inflation Reduction Act’s Drug Price Negotiation Program. FDA’s approval of WEZLANA has also been raised as a pertinent fact in one of the pending challenges to the Drug Price Negotiation Program.

Drug Pricing 53

Drug Pricing Biosimilars 53

PharmExec

JANUARY 31, 2025

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Drug Pricing 52

Drug Pricing 52

Pharmaceutical Technology

FEBRUARY 15, 2024

In 2023, Japan approved the outlines of its drug pricing and repricing reform for NHI-listed drugs that will take effect in FY 2024 and FY 2025.

Drug Pricing 52

Drug Pricing 52

HealthPartners

MAY 5, 2021

Understanding pharmacy benefit management and drug pricing The U.S. prescription drug supply chain is extraordinarily complex. It captures, with strong simplification, the web of stakeholders in the prescription drug market and the myriad of contractual agreements that drives the cash flows between them. billion by 2025.

Drug Pricing 40

Drug Pricing Mail-Order Pharmacies Pharmaceutical Manufacturing Pharmaceutical Companies 40

Express Pharma

MARCH 26, 2025

Japans Ministry of Health, Labor, and Welfare (MHLW) announced a new 10-year government fund in January 2025 to support innovative drug development. Sahu adds, Japans aging population is driving demand for innovative treatments in regenerative medicine, personalised therapies, and AI-driven drug discovery.

Drug Development 66

Drug Development Drug Pricing 66

Pharmaceutical Technology

JULY 21, 2022

Pharma giant AstraZeneca also plans to make its supply chain carbon-negative by 2030; to reduce its Scope 1 emissions by 20%, Scope 2 emissions by 95%, and Scope 3 emissions by 25% per $1m of sales by 2025. According to the World Health Organization (WHO), two billion people lack access to essential or basic drugs.

Drug Pricing 52

Drug Pricing Vaccines 52

FDA Law Blog: Biosimilars

DECEMBER 3, 2023

On November 17th, CMS issued its final guidance on the Discount Program in which it responded to public comments and provided updated guidance for the Discount Program for 2025 and 2026. The manufacturer’s agreement must cover all its labeler codes that contain an applicable drug or a selected drug. Final Guidance at 2.

Labelling 105

Labelling Drug Pricing Compounding Payment Processing 105

Big Molecule Watch

AUGUST 25, 2023

The Inflation Reduction Act’s Medicare Drug Price Negotiation Program will kick off next week. There are reports that the White House may announce the list of selected drugs even before that deadline, on Tuesday, August 29 th. Before the IRA, the government could not set prices for any drugs covered by Medicare.

Drug Pricing 40

Drug Pricing Biosimilars Insurance Coverage and Processing Labelling 40

Putting Patients First Blog

OCTOBER 15, 2024

Important Changes to Medicare as Open Enrollment Season Begins October 15, 2024 By: Allen Pinn, Coordinator, Policy Medicare Open Enrollment for 2025, which begins today and ends December 7, is an opportunity for Medicare enrollees to choose a new plan under Medicare Advantage, Medicare Part D, or traditional Medicare.

Drug Pricing 52

Drug Pricing 52

Big Molecule Watch

JANUARY 14, 2025

The Aflibercept BPCIA Litigations Continue Into 2025 As was the case with last years recap of 2023 , Regenerons litigation against multiple aflibercept biosimilar competitors tops our chart this year. Oral argument in Regenerons appeal occurred earlier today, January 14, 2025. A panel hearing is scheduled for January 30, 2025.

Biosimilars 45

Biosimilars Drug Pricing 45

Digital Pharmacist

JANUARY 4, 2024

CVS Health recently announced two new pricing models launching in 2025—CVS CostVantage (Focused on CVS as the Provider) and CVS Caremark TrueCost (Focused on CVS as the Payer)—which are intended to “drive aligned incentives and deliver a more transparent and sustainable reimbursement model” according to CVS Health’s press release.

Drug Pricing 52

Drug Pricing Independent Pharmacies Prescription Management Pharmacy Management 52

Putting Patients First Blog

MARCH 21, 2024

Out-of-Pocket Cap and Medicare Prescription Payment Plan (Smoothing) The IRA makes several changes to the Medicare Part D prescription drug program that help patients afford their drugs. Starting in 2025 there will be a cap on out-of-pocket costs set at $2,000 a year.

Drug Pricing 52

Drug Pricing 52

Putting Patients First Blog

MARCH 21, 2024

Out-of-Pocket Cap and Medicare Prescription Payment Plan (Smoothing) The IRA makes several changes to the Medicare Part D prescription drug program that help patients afford their drugs. Starting in 2025 there will be a cap on out-of-pocket costs set at $2,000 a year.

Drug Pricing 52

Drug Pricing 52

pharmaphorum

JANUARY 13, 2023

Everyone agrees that cell and gene therapies are poised for an explosion, with far more drugs in the pipeline than are currently approved, and the FDA predicts it will clear 10 to 20 per year by 2025. “We need to fix this fast, or else there is going to be more legislation that is going to target us.

Drug Pricing 98

Drug Pricing Immunity Immunization Vaccines 98

Big Molecule Watch

JANUARY 10, 2025

As 2025 begins, we would like to reflect on last years regulatory developments in the biologics and biosimilars space. Here are some of the top regulatory developments from 2024. FDA Approvals in 2024 There were 17 FDA approvals of Biologic License Applications (BLAs), including for Autolus Inc.’s

Biosimilars 45

Biosimilars Drug Pricing Labelling Communication 45

Pharma in Brief

JANUARY 10, 2024

Expected highlights for 2024 include a final PTA regime, more details on PMPRB drug pricing guidelines and national pharmacare, and fall-out from the US mass drug importation program targeting Canadian medicines. The amendments are scheduled to come into force no later than January 1, 2025. Regulatory changes.

Drug Pricing 52

Drug Pricing Documentation Biosimilars Vaccines 52

Big Molecule Watch

JANUARY 25, 2024

The licensure and marketing of WEZLANA could affect negotiations with CMS regarding Medicare pricing for STELARA under the Inflation Reduction Act’s Drug Price Negotiation Program. According to a reported statement from Amgen, its settlement agreement with Janssen allows Amgen to sell WEZLANA “no later than January 1, 2025.”

Biosimilars 45

Biosimilars Labelling Drug Pricing 45

Putting Patients First Blog

JANUARY 27, 2025

8 (2023), [link] 13 American Medical Association, “Prior Authorization Delays Care and Increases Health Care Costs,” accessed January 2, 2025, [link] www.ama-assn.org/practice- management/prior-authorization/prior-authorization-delays-care-and-increases-health-care. Accessed January 2, 2025. 14 National Health Council.

Insurance Coverage and Processing 40

Insurance Coverage and Processing Biosimilars Communication Department of Veterans Affairs 40

Putting Patients First Blog

APRIL 14, 2023

We also note that CMS’ March 1, 2025 deadline for publishing explanations of 2026 MFPs coincides with deadlines for stakeholders to submit information on selected drugs for IPAY 2027, which will make it difficult for stakeholders to glean insight from the explanations to refine and improve their data.

Drug Pricing 40

Drug Pricing Drug Development Documentation Communication 40

STAT

SEPTEMBER 23, 2022

… The White House is pitching an added benefit to the recent drug-pricing reform package: lower cancer death rates , STAT explains. A  A new analysis by the Council of Economic Advisers focused on a provision that caps Medicare out-of-pocket costs for pharmacy drugs at $2,000 a year, starting in 2025.

Drug Pricing 226

Drug Pricing Packaging 226

STAT

AUGUST 30, 2024

The Biden administration recently announced that it will use taxpayer dollars to “ stabilize ” Medicare Part D (prescription drug coverage) premiums. But in 2025, they are expected to nearly triple. These premiums had been remarkably stable since 2010, growing slower than inflation. Read the rest…

Drug Pricing 340

Drug Pricing 340

STAT

JULY 9, 2024

Moreover, the FTC found the prescription drug market is “highly concentrated” because the largest PBMs are owned by insurers and, in turn, own specialty, mail order or retail pharmacies.

Drug Pricing 273

Drug Pricing 273

STAT

JULY 9, 2024

Pharma’s dwindling alliances The pharmaceutical industry didn’t have many friends that stuck up for it when Democrats passed a historic drug pricing law in 2022. By the beginning of 2025, even many of the industry’s remaining allies will have left Congress, Rachel Cohrs Zhang reports.

Drug Pricing 228

Drug Pricing Hospitals 228

STAT

MAY 1, 2023

But revised legislation prepared for a Tuesday markup by the Senate health committee shows that the changes would now take effect 30 months after the law is passed, no sooner than November 2025. The original date that pharmacy benefit manager reforms were supposed to take effect was Jan.

Documentation 246

Documentation Drug Pricing 246

STAT

SEPTEMBER 23, 2022

WASHINGTON — The White House is pitching an added benefit to Democrats’ recent drug pricing reform package: lower cancer death rates. A new analysis by the Council of Economic Advisers focused on the new law capping Medicare patients’ out-of-pocket costs for pharmacy drugs at $2,000 per year, starting in 2025.

Drug Pricing 245

Drug Pricing Packaging 245

STAT

JANUARY 7, 2025

It’s the first real workweek of 2025 and we’re already starting to get a pickup in news again, so let’s get straight into it. Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning. Read the rest…

Drug Pricing 265

Drug Pricing Drug Development 265